Our findings are consistent with the previous study where we examined peripheral CD45+ immune cell populations in spleens and blood of 4T1 tumor-bearing mice treated with GEM or vehicle control (Figures S2 and S3). This evidence concerns the gene PTPRC and neoplasm.